Ranbaxy: Riding on the US wave - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Ranbaxy: Riding on the US wave

Apr 29, 2003

Powered by a 161% growth in exports, Ranbaxy Laboratories Limited, has reported a 51% growth in consolidated net sales and nearly 94% sales growth on a standalone basis in the March quarter. The company reported a 77% growth in net profits (consolidated) and nearly 195% growth in standalone profits.

Consolidated numbers
(Rs m) 1QFY03 1QFY04 Change FY03
Net sales 7,345 11,102 51.2% 37,138
Other Operating Income 118 539 356.8% 1,379
Total operating income 7,463 11,641 56.0% 38,517
Other income 51 77 51.0% 245
Operating expenses 6,302 9,018 43.1% 30,606
Operating profit 1,161 2,623 125.9% 7,911
Operating profit margin (%) 15.6% 22.5% 44.8% 20.5%
Interest  198 77 -61.1% 387
Depreciation 296 372 25.7% 951
Profit before tax and extraordinary items 718 2,251 213.5% 6,818
Extra-ordinary Items 818 102 -87.5% 876
Technology Licencing Income 0 0 - 640
Tax 558 614 10.0% 1856
Profit after Tax/(Loss) 978 1,739 77.8% 6,478
Minority interests 1 10 900.0% 8
PAT after minority interests 977 1,729 77.0% 6,470
Net profit margin (%) 13.3% 15.6%   17.4%
No. of Shares (eoy) (m) 115.9 185.5   185.5
Earnings per share* 21.1 37.3   34.9
*(annualised)        
Current P/e ratio   18.1   19.3

Overseas markets reported strong growth largely led by the generics spurt. Non-India revenues now form 81% of the company's global sales. This region reported over 78% growth during the quarter. US has emerged as Ranbaxy's largest market (accounting for 48% of global revenues). This region has grown by a strong 120% YoY during 1QFY04. In January 2003, Bayer had launched its Cipro once-a-day product (500mg) in the US market. This seems to be the likely reason for the strong US led growth. Europe too, grew by a strong 52% YoY, now accounting for over 10% of revenues. The growth in Europe region was largely spearheaded by UK, with a growth of 56% YoY. Germany also performed well with a growth of 82% over the corresponding period, though on a relatively smaller base.

Regional sales break-up
(US$ m) 1QFY03 1QFY04 Change % of sales in 1QFY04
India (Rs m) 2,353 2,202 -6.4% 19.8%
US 51 112 120.0% 48.0%
Europe (UK, Russia, Germany, Poland) 16 24 52.0% 10.3%

India (i.e. the domestic market), was the only soft spot in the company's performance. The company's sales dipped by a marginal 6.4% during the March quarter, in keeping with the overall slowdown in the domestic industry. As per ORG figures released by the company, the industry witnessed a flat growth of 0.7% during the March quarter. This is much slower than the 8% industry growth witnessed in the year 2002. The company also attributed the dip in domestic sales to the uncertainty over VAT, coupled with the continuous declining trend in the anti-infective market over the past eight months. India's share in Ranbaxy's revenues which stood at 32% in March quarter last year, is currently just below 20% of revenues.

Standalone numbers
(Rs m) 1QFY03 1QFY04 Change FY03
Net Sales 5,289 10,249 93.8% 27,686
Other operating income 181 648 258.0% 1,794
Other Income 33 56 69.7% 199
Total expenditure 4,517 7,470 65.4% 23,082
Operating Profit (EBDIT) 953 3,427 259.6% 6,398
Operating Profit Margin (%) 18.0% 33.4%   23.1%
Interest 131 6 -95.4% 208
Depreciation 198 179 -9.6% 594
Profit before Tax 657 3,298 402.0% 5,795
Extraordinary items 564 49 -91.3% 1,339
Tax 272 549 101.8% 898
Profit after Tax/(Loss) 949 2,798 194.8% 6,236
Net profit margin (%) 17.9% 27.3%   22.5%
No. of Shares (eoy) (m) 115.9 185.5   185.5
Earnings per share* 20.5 60.3   33.6
*(annualised)        
Current P/e ratio   11.2   20.0

Ranbaxy, which is India's largest pharma company, has emerged as a true Indian MNC. The company now sells its products in over 70 countries, with ground operations in 25 countries and manufacturing operations in 7 countries. The company's R&D expenses have shot up from 2.3% of total operating income (consolidated) last year to 5.3% during 1QFY04. This fact stresses on the company's continued focus on the global market. During the quarter, Ranbaxy received 5 approvals, taking the cumulative number of approvals to 63 (33 approvals are still pending).

Sales break-up
(Rs m) 1QFY03 1QFY04 Change
Domestic 2,353 2,202 -6.4%
Exports 3,176 8,291 161.1%
Less: Trade discounts 240 244 1.7%
Net Sales (standalone) 5,289 10,249 93.8%

At Rs 674, the stock is trading at 18.1x annualised 1QFY04 earnings (consolidated). Ranbaxy continues to reap the rewards of its strategy to set up presence across the globe. The company had clocked 148% net profit rise in FY03 too, backed by a strong 38% topline increase. Owing to the stupendous rates of growth, the company's valuations look to be on the lower side. But as we have seen in the past, Indian generic companies have had a string of volatile quarters and the performance is not a benchmark of things to come. But we are enthused by the company's strong march forward globally.


Equitymaster requests your view! Post a comment on "Ranbaxy: Riding on the US wave". Click here!

  

More Views on News

Sorry! There are no related views on news for this company/sector.

Most Popular

How the 8-Year Cycle Can Help Identify Multibaggers (Fast Profits Daily)

Sep 11, 2020

This is how you can apply the greed and fear cycle in the market to pick stocks.

Why am I Recommending Caution? (Fast Profits Daily)

Sep 9, 2020

This is why I have changed my short-term view on the market.

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

This Could Be the Best September for Auto Stocks (Profit Hunter)

Sep 11, 2020

Here's why I think this month could be a great for auto stocks.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

RANBAXY LAB SHARE PRICE


Apr 1, 2015 (Close)

TRACK RANBAXY LAB

  • Track your investment in RANBAXY LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MARKET STATS